Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody
Open accessThe DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
Abstract
Despite promising results in the use of anti-epidermal growth factor receptor (EGFR) Abs for cancer therapy, several issues remain to be addressed. An increasing emphasis is being placed on immune effector mechanisms. It has become clear for other Abs directed to tumor targets that their effects involve the adaptive immunity, mainly by the contribution of Fc region-mediated mechanisms. Given the relevance of EGFR signaling for tumor biology, we wonder whether the oncogene inhibition could contribute to Ab-induced vaccine effect. In a mouse model in which 7A7 (an anti-murine EGFR Ab) and AG1478 (an EGFR-tyrosine kinase inhibitor) displayed potent antimetastatic activities, depletion experiments revealed that only in the case of the Ab, the effect was dependent on CD4(+) and CD8(+) T cells. Correspondingly, 7A7 administration elicited a remarkable tumor-specific CTL response in hosts. Importantly, experiments using 7A7 F(ab')(2) suggested that in vivo Ab-mediated EGFR blockade may play an important role in the linkage with adaptive immunity. Addressing the possible mechanism involved in this effect, we found quantitative and qualitative differences between 7A7 and AG1478-induced apoptosis. EGFR blocking by 7A7 not only prompted a higher proapoptotic effect on tumor metastases compared with AG1478, but also was able to induce apoptosis with immunogenic potential in an Fc-independent manner. As expected, 7A7 but not AG1478 stimulated exposure of danger signals on tumor cells. Subcutaneous injection of 7A7-treated tumor cells induced an antitumor immune response. This is the first report, to our knowledge, of a tumor-specific CTL response generated by Ab-mediated EGFR inhibition, suggesting an important contribution of immunogenic apoptosis to this effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At least in part, this reflects the ability of EGFR-targeted agents to induce ICD (Garrido et al., 2011; Pozzi et al., 2016) (Box 1) and the consequent exposure of the ''eat-me'' signal calreticulin (CALR) coupled to the downregulation of the ''don't eat me'' signal CD47 on the surface of malignant cells (Nigro et al., 2019).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Garrido et al., 2011
In the citing paper
“DAMPemission by lung cancer cells, linked to DC maturation in vitro”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Garrido et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
Albert, M. L., Sauter, B., & Bhardwaj, N. (1998) · Nature · doi:10.1038/32183 · Cited by 2,349
SYFPEITHI: database for MHC ligands and peptide motifs
Rammensee, H. G., Bachmann, J., Emmerich, N. P. N., Bachor, O. A., & Stevanović, S. (1999) · Immunogenetics · doi:10.1007/s002510050595 · Cited by 2,314
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
How dying cells alert the immune system to danger
Kono, H., & Rock, K. L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2215 · Cited by 1,737
Corpse clearance defines the meaning of cell death
Savill, J., & Fadok, V. (2000) · Nature · doi:10.1038/35037722 · Cited by 1,547
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176
Research works printed but not linked: 2
- Baselga, J., R. Herbst, P. LoRusso, D. Rischin, M. Ranson, R. Plummer, E. Raymond, A.-M. Maddox, S. Kaye, D. Kieback, et al. 2000. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor re- ceptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tu- mor types: evidence of activity and good tolerability. Proc. Am. Soc. Clin. Oncol. 19: 2000.
- Liu, B., M. Fang, M. Schmidt, Y. Lu, J. Mendelsohn, and Z. Fan. 2000. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br. J. Cancer 82: 1991-1999.
Cited by
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Detection of immunogenic cell death and its relevance for cancer therapy
Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Garg, A. D., Galluzzi, L., Apetoh, L., Baert, T., Birge, R. B., Bravo-San Pedro, J. M., Breckpot, K., Brough, D., Chaurio, R., Cirone, M., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00588 · Cited by 410
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
Inoue, H., & Tani, K. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.84 · Cited by 347
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Pol, J., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008866 · Cited by 305
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Liu, P., Zhao, L., Pol, J., Levesque, S., Petrazzuolo, A., Pfirschke, C., Engblom, C., Rickelt, S., Yamazaki, T., Iribarren, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09415-3 · Cited by 302
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Pozzi, C., Cuomo, A., Spadoni, I., Magni, E., Silvola, A., Conte, A., Sigismund, S., Ravenda, P. S., Bonaldi, T., Zampino, M. G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4078 · Cited by 292
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Garg, A. D., More, S., Rufo, N., Mece, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 276
Garg, A. D., & Agostinis, P. (2014) · Photochemical & Photobiological Sciences · doi:10.1039/c3pp50333j · Cited by 276
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265
Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies
Wang, Q., Ju, X., Wang, J., Fan, Y., Ren, M., & Zhang, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.08.028 · Cited by 264
Inducers of immunogenic cancer cell death
Dudek, A. M., Garg, A. D., Krysko, D. V., De Ruysscher, D., & Agostinis, P. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.01.005 · Cited by 250
Garg, A. D., Dudek-Peric, A. M., Romano, E., & Agostinis, P. (2015) · The International Journal of Developmental Biology · doi:10.1387/ijdb.150061pa · Cited by 240
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., De Ruysscher, D., Tejpar, S., Vandenberghe, P., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 227
Danger signalling during cancer cell death: origins, plasticity and regulation
Garg, A. D., Martin, S., Golab, J., & Agostinis, P. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.48 · Cited by 226
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Workenhe, S. T., & Mossman, K. L. (2014) · Molecular Therapy · doi:10.1038/mt.2013.220 · Cited by 203
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy
Adkins, I., Fucikova, J., Garg, A. D., Agostinis, P., & Špíšek, R. (2014) · OncoImmunology · doi:10.4161/21624011.2014.968434 · Cited by 200
Jia, Y., Li, X., Jiang, T., Zhao, S., Zhao, C., Zhang, L., Liu, X., Shi, J., Qiao, M., Luo, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32191 · Cited by 164
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Otano, I., Ucero, A. C., Zugazagoitia, J., & Paz-Ares, L. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00718-x · Cited by 184
Trial Watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Aranda, F., Eggermont, A., Galon, J., Sautès-Fridman, C., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27878 · Cited by 150
Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152934 · Cited by 131
Ruan, R., Li, L., Li, X., Huang, C., Zhanmin, Z., Zhong, H., Zeng, S., Shi, Q., Yang, X., Zeng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01761-7 · Cited by 144
Cancer immunogenicity, danger signals, and DAMPs: What, when, and how?
Garg, A. D., Dudek, A. M., & Agostinis, P. (2013) · BioFactors · doi:10.1002/biof.1125 · Cited by 108
Immunogenic Apoptotic Cell Death and Anticancer Immunity
Vandenabeele, P., Vandecasteele, K., Bachert, C., Krysko, O., & Krysko, D. V. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-39406-0_6 · Cited by 110
Immunogenic Cell Death-Based Cancer Vaccines
Jin, M.-Z., & Wang, X.-P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697964 · Cited by 99
Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC
Li, X., Lian, Z., Wang, S., Xing, L., & Yu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.005 · Cited by 104
Xu, C., Yu, Y., Sun, Y., Kong, L., Yang, C., Hu, M., Yang, T., Zhang, J., Hu, Q., & Zhang, Z. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201905213 · Cited by 84
Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress
Garg, A. D., Maes, H., van Vliet, A. R., & Agostinis, P. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.975089 · Cited by 80
Kang, S.-H., Keam, B., Ahn, Y.-O., Park, H.-R., Kim, M., Kim, T. M., Kim, D.-W., & Heo, D. S. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1515057 · Cited by 72
Wu, Q., Allouch, A., Martins, I., Brenner, C., Modjtahedi, N., Deutsch, É., & Perfettini, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00613 · Cited by 79
Nigro, A., Ricciardi, L., Salvato, I., Sabbatino, F., Vitale, M., Crescenzi, M. A., Montico, B., Triggiani, M., Pepe, S., Stellato, C., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03135 · Cited by 70
Hernández, Á., Juanes‐Velasco, P., Landeira‐Viñuela, A., Bareke, H., Montalvillo, E., Góngora, R., & Fuentes, M. (2021) · Cancers · doi:10.3390/cancers13112821 · Cited by 77
Rios‐Doria, J., Sabol, D., Chesebrough, J. W., Stewart, D., XU, L. L., Tammali, R., Cheng, L., Du, Q., Schifferli, K. P., Rothstein, R., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1040 · Cited by 55
Okuyama, K., Naruse, T., & Yanamoto, S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02691-4 · Cited by 59
Dendritic cells and their role in tumor immunosurveillance
Strioga, M. M., Schijns, V. E. C. J., Powell, D. J., Pašukonienė, V., Dobrovolskienė, N., & Michálek, J. (2012) · Innate Immunity · doi:10.1177/1753425912449549 · Cited by 65
A view on EGFR-targeted therapies from the oncogene-addiction perspective
Pérez, R., Crombet, T., de León, J., & Moreno, E. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00053 · Cited by 50
Self-citationvan Vliet, A. R., Martin, S., Garg, A. D., & Agostinis, P. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.010 · Cited by 46
Calvillo-Rodríguez, K. M., Mendoza-Reveles, R., Gómez‐Morales, L., Uscanga‐Palomeque, A. C., Karoyan, P., Martínez‐Torres, A. C., & Rodríguez-Padilla, C. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2054305 · Cited by 46
EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects
Pérez, R., Moreno, E., Garrido, G., & Crombet, T. (2011) · Cancers · doi:10.3390/cancers3022014 · Cited by 45
Self-citationYang, Y., Nam, G., Kim, G. B., Kim, Y. K., & Kim, I. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.007 · Cited by 40
Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
Garrido, G., Rabasa, A., Garrido, C., Chao, L., Garrido, F., Garcia-Lora, A. M., & Sánchez-Ramírez, B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00595 · Cited by 41
Self-citationGarrido, G., Rabasa, A., Garrido, C., López, A., Chao, L., Garcia-Lora, A. M., Garrido, F., Fernandez, L. E., & Sánchez, B. (2013) · Oncogene · doi:10.1038/onc.2013.288 · Cited by 37
Self-citationSun, C., Wang, H., Mao, S., Ji, L., Li, S., & Wang, J. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.02.007 · Cited by 37
Lopes, J., Ferreira-Gonçalves, T., Figueiredo, I. V., Rodrigues, C. M. P., Ferreira, H. A., Ferreira, D., Viana, A. S., Faísca, P., Gaspar, M. M., Coelho, J. M. P., et al. (2021) · Biomolecules · doi:10.3390/biom11040511 · Cited by 33
Endoplasmic reticulum stress in the cellular release of damage-associated molecular patterns
Chuang, A. W., Kepp, O., Kroemer, G., & Bezu, L. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.11.006 · Cited by 34
Immunotherapy in colorectal cancer
Agarwal, P., Le, D. T., & Boland, P. M. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.03.002 · Cited by 35
Staudacher, A. H., Al‐Ejeh, F., Fraser, C. K., Darby, J. M., Roder, D. M., Ruszkiewicz, A. R., Manavis, J., & Brown, M. P. (2014) · EJNMMI Research · doi:10.1186/2191-219x-4-2 · Cited by 30
Combinations using checkpoint blockade to overcome resistance
Morganti, S., & Curigliano, G. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1148 · Cited by 26
Romano, S., Moura, V., Simões, S., Moreira, J. N., & Gonçalves, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-25816-8 · Cited by 23
Eisa, N. H., Crowley, V. M., Elahi, A., Kommalapati, V. K., Serwetnyk, M. A., Llbiyi, T., Lu, S., Kainth, K., Jilani, Y., Marasco, D., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108308 · Cited by 21
Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities
Ren, X., Li, Y., Nishimura, C., & Zang, X. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.009 · Cited by 20
Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer
Wang, D., Cong, J., Fu, B., Zheng, X., Sun, R., Tian, Z., & Wei, H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.043 · Cited by 20
Huang, Z., & Hu, H. (2021) · Molecules · doi:10.3390/molecules26020511 · Cited by 17
Deligne, C., Milcent, B., Josseaume, N., Teillaud, J., & Sibéril, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00950 · Cited by 16
Antitumor and cytotoxic properties of a humanized antibody specific for the GM3(Neu5Gc) ganglioside
Dorvignit, D., García-Martínez, L., Rossin, A., Sosa, K., Viera, J., Hernández, T., Mateo, C., Hueber, A., Mesa, C., & López‐Requena, A. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.07.008 · Cited by 16
He, X., Cruz, J. L. G., Joseph, S. R., Pett, N., Chew, H. Y., Tuong, Z. K., Okano, S., Kelly, G., Veitch, M., Simpson, F., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24242 · Cited by 15
Advances and prospects of drug clinical research in colorectal cancer in 2022
Su, D., Liu, C., Cui, J., Tang, J., Ruan, Y., & Zhang, Y. (2023) · Cancer Innovation · doi:10.1002/cai2.62 · Cited by 11
Azevedo, J. D., Mourtada, J., Bour, C., Devignot, V., Schultz, P., Borel, C., Pencreach, E., Mellitzer, G., Gaiddon, C., & Jung, A. C. (2022) · Cells · doi:10.3390/cells11182866 · Cited by 16
Kashefizadeh, A., & Kazemizadeh, H. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02949-x · Cited by 11
Bourillon, L., Demontoy, S., Lenglet, A., Zampieri, A., Fraisse, J., Jarlier, M., Boissière‐Michot, F., Perrochia, H., Rathat, G., Garambois, V., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.12.020 · Cited by 12
HER1-based vaccine: Simultaneous activation of humoral and cellular immune response
Bergado, G., Fernández, D. R. H., Mazorra, Z., & Ramírez, B. S. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.05.002 · Cited by 9
From targeted therapy to a novel way: Immunogenic cell death in lung cancer
Xu, J., Xiong, Y., Xu, Z., Xing, H., Zhou, L., & Zhang, X. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1102550 · Cited by 11
Fernández‐Marrero, Y., & López‐Requena, A. (2011) · mAbs · doi:10.4161/mabs.3.6.17770 · Cited by 8
Immunotherapy and Complexity: Overcoming Barriers to Control of Advanced Cancer
Lage, A. (2014) · MEDICC Review · doi:10.37757/mr2014.v16.n3-4.13 · Cited by 9
Rabasa, A., Mesa, J. E. G., Rodríguez‐Vera, L., López, A., Ramírez, B. S., & Hidalgo, G. G. (2012) · ISRN Pharmacology · doi:10.5402/2012/417515 · Cited by 7
Self-citationSkibbe, K., Brethack, A.-K., Sünderhauf, A., Ragab, M., Raschdorf, A., Hicken, M., Schlichting, H., Preira, J., Brandt, J., Castven, D., et al. (2021) · Cancers · doi:10.3390/cancers13225817 · Cited by 6
Yang, Z., Wang, L., & Kang, F. (2025) · International Journal of Cancer · doi:10.1002/ijc.35496 · Cited by 4
Deligne, C., & Gros, L. (2019) · médecine/sciences · doi:10.1051/medsci/2019194 · Cited by 7
Lotsberg, M. L., Chen, S., Dhakal, S., Lorens, J. B., Baguley, B. C., Chouaïb, S., & Engelsen, A. S. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819609-0.00008-0 · Cited by 4
Garrido, G., Rabasa, A., & Sánchez, B. (2013) · OncoImmunology · doi:10.4161/onci.26904 · Cited by 3
Self-citationEGFR-targeting therapy as an evolving concept: learning from nimotuzumab clinical development.
Pérez, R., & Moreno, E. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2013.11.09 · Cited by 4
Self-citationImmunogenic Cell Death in Cancer
Humeau, J., Naour, J. L., Kroemer, G., & Pol, J. G. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2022_121 · Cited by 2
Murganić, B., Krajnović, T., Đunđerović, D., Kazimir, A., Tanić, N., Tanić, N., Hey‐Hawkins, E., Maksimović‐Ivanić, D., & Mijatović, S. (2026) · Molecules · doi:10.3390/molecules31091376 · Cited by 1
Lage, A., & Romero, T. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.04.004 · Cited by 1
Immunogenic clearance-mediated cancer vaccination
Nam, G., Yang, Y., & Kim, I. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102983-1.00020-x · Cited by 1
Nimotuzumab: A Humanized Anti‐EGFR Antibody
Crombet, T. (2014) · doi:10.1002/9783527682423.ch61 · Cited by 1
Del nuevo producto biológico para el cáncer al impacto en la salud poblacional
Dávila, A. L., & Crombet, T. (2012) · Revista Cubana de Salud Pública · doi:10.1590/s0864-34662012000500011
Immunogénicité de la chimiothérapie
Michels, J., Yamasaki, T., & Apétoh, L. (2015) · ONCOLOGIE · doi:10.1007/s10269-015-2543-y
Chen, C., & Yang, L. (2023) · Research Square · doi:10.21203/rs.3.rs-2620356/v1
Crizotinib-Induced Immunogenic Cell Death in Non-Small Cell Lung Cancer
Liu, P. (2018) · theses.fr (ABES) · doi:10.70675/ed550df1z9febz41d6z9846z294a6695b865
Inhibition of Transcription by Dactinomycin Reveals a New Characteristic of Immunogenic Cell Stress
Humeau, J. (2019) · theses.fr (ABES) · doi:10.70675/e42505daza57fz459az9dc5z1ef744d25b38
Modulation of tumor immunogenicity with AMPK activation in acute myeloid leukemia
Mondésir, J. (2021) · theses.fr (ABES) · doi:10.70675/2693bda5ze768z4bf0z857bze1eb8ccccc80
Tian, A.-L. (2022) · theses.fr (ABES) · doi:10.70675/bf82f2b6zc957z4d06z9332zd8b7d5ba24a4
Milian, L. M., Geindreau, M., Pignol, C., & Végran, F. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00612-3
Metadata
- Authors
- Garrido, G., Rabasa, A., Sánchez, B., López, M. V., Blanco, R., López, A., Hernández, D. R., Pérez, R., & Fernández, L. E.
- Affiliations
- Center of Molecular Immunology (Cuba) (CU)
- Quality Control Department, Quality Direction, Center of Molecular Immunology , Havana 11600 ,
- Tumor Immunology Direction, Molecular Immunology Institute, Center of Molecular Immunology , Havana 11600 ,
- Innovative Direction, Molecular Immunology Institute, Center of Molecular Immunology , Havana 11600 ,
- Corresponding author
- Garrido, Greta
- Rabasa, Ailem
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11
- Volume
- 187
- Issue
- 10
- Pages
- 4954-4966
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2144107170
- Cited by
- 91
- References
- 64
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 8 · 2022: 5 · 2021: 8 · 2020: 10 · 2019: 8 · 2018: 8 · 2017: 4 · 2016: 2 · 2015: 9 · 2014: 9 · 2013: 9 · 2012: 6
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- epidermal growth factor receptor, anti-EGFR monoclonal antibody, AG1478, EGFR tyrosine kinase inhibitors, tumor-specific cytotoxic T lymphocytes, metastasis, adaptive immunity, damage-associated molecular patterns, antitumor immunity, CD4 and CD8 T cells
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody Specificity, Cells, Cultured, Female, Immunoglobulin Fc Fragments, Lung Neoplasms, Melanoma, Experimental, Mice, Inbred C57BL, T-Lymphocytes, Cytotoxic, Apoptosis, Carcinoma, Lewis Lung, Antibodies, Blocking, Cell Line, Tumor, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.